Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    Bupropion

    go.drugbank.com/drugs/DB01156
    ApprovedInvestigational

    in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor. … [L6562] Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated

    Products: ODRANAL® 150 MG TABLETASRECUBIERTAS DE LIBERACION PROLONGADA
  2. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol

  3. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.[L11575] … the approval of fidaxomicin.

  4. Drug

    Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10076
    Approved

    The vaccine contains the *Haemophilus influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the *H. influenzae* type b strain 1482 … The toxoid antigen is purified and toxin-inactivated.

    Mixtures: PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  5. Drug

    Clonazepam

    go.drugbank.com/drugs/DB01068
    ApprovedIllicitInvestigational

    [FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. … in the treatment of the aforementioned medical conditions.

    Synonyms: 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one, 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-oneProducts: RIVOTRIL ® TABLETAS DE 2.0 MG.
  6. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    11.5 kg, with growth failure due to insufficient growth hormone secretion. … [L36380] It was later approved by the European Commission on 13 January 2022.[L39900]

  7. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. … [L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]

    Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur Infusion
  8. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making

  9. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    Umbilical blood cord cells are expanded _ex-vivo_ and [nicotinamide] (a form of vitamin B3) is used as an active agent in the culture system to inhibit the differentiation and increase the functionality … In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability.

  10. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin … [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with